Sign In

Nicholas Restifo, MD

Cancer Immunotherapy Explorer and Entrepreneur

Nicholas Restifo, MD is a prominent figure in the field of cancer immunotherapy with an extensive background in research and development. He currently serves as the Chief Scientist and Head of R&D at Marble Therapeutics, a company based in Boston, Massachusetts.3

Career Highlights

Dr. Restifo has been pioneering new cell-based immunotherapies since 1989, including work on TIL (tumor-infiltrating lymphocytes), TCR-gene modified T cells, CAR-T cells, checkpoint blockade, and mechanisms of lymphodepletion.1 His career spans several decades and includes significant positions:

  • Marble Therapeutics: Co-founder and Chief Scientist45
  • National Institutes of Health: Principal Investigator for 30 years (July 1989 - July 2019)1
  • Lyell Immunopharma: Executive Vice President of Research (July 2019 - February 2022)1
  • RestifoPartners, LLC: Founder and CEO (February 2022 - Present)1

Education and Early Career

  • Bachelor's degree in Natural Sciences from Johns Hopkins University (1979-1983)1
  • Doctor of Medicine (MD) from New York University School of Medicine (1983-1987)1
  • Postdoctoral Fellowship at Memorial Sloan Kettering Cancer Center (July 1988 - June 1989)1

Research Focus

Dr. Restifo is known as a "Cancer Immunotherapy Explorer".1 His work has been instrumental in advancing T cell-based immunotherapy, which has become a crucial area in cancer treatment.2 He has been involved in developing various innovative approaches to cancer immunotherapy throughout his career.

Current Work

At Marble Therapeutics, Dr. Restifo is likely applying his extensive experience in cancer immunotherapy to develop new cell-based treatments. His recent activities suggest a continued focus on advancing therapies for various cancers, including lung cancer.6

Highlights

Apr 19 · oncodaily.com
Nicholas Restifo: When Nature is not enough - OncoDaily
Nicholas Restifo: When Nature is not enough - OncoDaily
Apr 9 · oncodaily.com
Nicholas Restifo: Advancing the Fight Against Lung Cancer with TIL ...
Feb 7 · nature.com
Turbocharged CAR-T cells melt tumours in mice — using a trick from ...

Related Questions

What are some of the key achievements of Nicholas Restifo in cancer immunotherapy?
How did Nicholas Restifo contribute to the development of CAR-T cell therapies?
What is the role of Marble Therapeutics in the field of cancer immunotherapy?
How has Nicholas Restifo's work at Lyell Immunopharma impacted his career?
What are the main focus areas of RestifoPartners, LLC?
Nicholas Restifo, MD
Nicholas Restifo, MD, photo 1
Nicholas Restifo, MD, photo 2
Add to my network

Experience

Founder and CEO at Restifo Partners, LLC
Principal Investigator at National Institutes of Health, July 1989 - July 2019

Education

Doctor of Medicine - MD, Medicine from New York University, 1983 - 1987, Principal Investigator, Cancer Immunotherapy at National Cancer Institute, 1989 - 2019

Location

Chevy Chase, Maryland, United States